加快 CAR-T/NK 疗法的普及--AlloCARs 和快速制造平台是改善多发性骨髓瘤治疗普及的必由之路吗？

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology Pub Date : 2024-10-01 DOI:10.1053/j.seminhematol.2024.09.001

Sridevi Rajeeve , Abhinav Hoskote , Sham Mailankody

{"title":"加快 CAR-T/NK 疗法的普及--AlloCARs 和快速制造平台是改善多发性骨髓瘤治疗普及的必由之路吗？","authors":"Sridevi Rajeeve , Abhinav Hoskote , Sham Mailankody","doi":"10.1053/j.seminhematol.2024.09.001","DOIUrl":null,"url":null,"abstract":"<div><div>While the advent of CAR-T therapies has heralded a new era of efficacious therapies in relapsed/refractory Multiple Myeloma, access continues to be a major limiting factor due to prolonged manufacturing times of autologous products and apheresis and/or manufacturing failures. Allogeneic adoptive cellular therapy products (CAR-T, CAR-NK), currently investigational, are “off-the-shelf” products that may address availability and manufacturing bottlenecks. Novel rapid manufacturing platforms that decrease adoptive cell therapy product development time by weeks are currently being tested in clinical trials and may additionally help bridge the demand-supply chasm. This review provides a comprehensive overview of allogeneic adoptive cellular therapies and rapid manufacturing platforms in development.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"61 5","pages":"Pages 297-305"},"PeriodicalIF":5.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?\",\"authors\":\"Sridevi Rajeeve , Abhinav Hoskote , Sham Mailankody\",\"doi\":\"10.1053/j.seminhematol.2024.09.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>While the advent of CAR-T therapies has heralded a new era of efficacious therapies in relapsed/refractory Multiple Myeloma, access continues to be a major limiting factor due to prolonged manufacturing times of autologous products and apheresis and/or manufacturing failures. Allogeneic adoptive cellular therapy products (CAR-T, CAR-NK), currently investigational, are “off-the-shelf” products that may address availability and manufacturing bottlenecks. Novel rapid manufacturing platforms that decrease adoptive cell therapy product development time by weeks are currently being tested in clinical trials and may additionally help bridge the demand-supply chasm. This review provides a comprehensive overview of allogeneic adoptive cellular therapies and rapid manufacturing platforms in development.</div></div>\",\"PeriodicalId\":21684,\"journal\":{\"name\":\"Seminars in hematology\",\"volume\":\"61 5\",\"pages\":\"Pages 297-305\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S003719632400091X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S003719632400091X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

虽然 CAR-T 疗法的出现预示着复发性/难治性多发性骨髓瘤的高效疗法进入了一个新时代，但由于自体产品的制造时间过长以及无细胞疗法和/或制造失败，获取仍是一个主要的限制因素。目前正在研究的异体采纳细胞疗法产品（CAR-T、CAR-NK）属于 "现成 "产品，可以解决供应和生产瓶颈问题。新型快速生产平台可将采用性细胞疗法产品的开发时间缩短数周，目前正在临床试验中进行测试，或许还能帮助弥合供需鸿沟。本综述全面概述了正在开发的异体收养细胞疗法和快速制造平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?

While the advent of CAR-T therapies has heralded a new era of efficacious therapies in relapsed/refractory Multiple Myeloma, access continues to be a major limiting factor due to prolonged manufacturing times of autologous products and apheresis and/or manufacturing failures. Allogeneic adoptive cellular therapy products (CAR-T, CAR-NK), currently investigational, are “off-the-shelf” products that may address availability and manufacturing bottlenecks. Novel rapid manufacturing platforms that decrease adoptive cell therapy product development time by weeks are currently being tested in clinical trials and may additionally help bridge the demand-supply chasm. This review provides a comprehensive overview of allogeneic adoptive cellular therapies and rapid manufacturing platforms in development.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in hematology 医学-血液学

CiteScore

6.20

自引率

2.80%

发文量

审稿时长

35 days

期刊介绍： Seminars in Hematology aims to present subjects of current importance in clinical hematology, including related areas of oncology, hematopathology, and blood banking. The journal''s unique issue structure allows for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering a variety of articles that present dynamic and front-line material immediately influencing the field. Seminars in Hematology is devoted to making the important and current work accessible, comprehensible, and valuable to the practicing physician, young investigator, clinical practitioners, and internists/paediatricians with strong interests in blood diseases. Seminars in Hematology publishes original research, reviews, short communications and mini- reviews.